We Treat Hep C


  • Updates to the FAQs: Included language on prescription for more than 4 weeks of DAA therapy. To read the updated language, click here



We Treat Hep C

The Michigan Department of Health and Human Services, Michigan Medicaid, and Michigan Department of Corrections partnered with research-based global biopharmaceutical company, AbbVie, in effort to eliminate hepatitis C through the We Treat Hep C Initiative.

Effective April 1, 2021 the antiviral MAVYRET® will no longer require prior authorization. Other direct-acting antivirals will require prior authorization and will be approved only when MAVYRET® is not clinically appropriate.  

Hepatitis C Elimination Plan 

In Michigan, it is estimated that at least 200,000 people are living with hepatitis C. Many people may not know they have hepatitis C; it can spread silently because people may have no symptoms for many years. When symptoms do appear, they often are a sign of advanced liver disease. The hepatitis C virus can lead to liver failure, liver cancer, and death, all preventable through the availability of highly effective treatment. Thus, the Michigan Department of Health and Human Services, with the support and expertise from critical partners across the state, created Michigan's Hepatitis C Elimination Plan to lay the groundwork for our state becoming hepatitis C free.

Press Release: MDHHS announces initiative to eliminate hepatitis C in Michigan 

Press Release: MDHHS launches We Treat Hep C Campaign aimed at providing timeline screening and treatment of Hepatitis C

Read Michigan's State Plan on Eliminating Hepatitis C

Viral Hepatitis National Strategic Plan, HHS 

Michigan - Hepatitis C: State of Medicaid Access Report Card 

National Viral Hepatitis Roundtable Press Release: Michigan Improves Access to Hepatitis C Treatment for Medicaid and Healthy Michigan Plan Patients

Related Links

Michigan Medicaid Program

Syringe Service Program Directory

Viral Hepatitis Data & Statistics


Resources for Providers
Resources for the Public